All News
Filter News
Found 59 articles
-
Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference
10/31/2022
Cognito Therapeutics announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer’s Disease, at the 2022 Clinical Trials in Alzheimer's Disease (CTAD), held November 29 - December 2, in San Francisco, CA.
-
Biogen and others are seeing the value in, particularly, non-prescription digital therapeutics, as complementary companion therapies to disease-modifying drugs.
-
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
8/1/2022
Cognito Therapeutics , announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for patients with Alzheimer’s Disease, according to new data presented at the Alzheimer’s Association International Conference 2022.
-
Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022
7/13/2022
Cognito Therapeutics , a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimer’s Association International Conference ® 2022 (AAIC ® ).
-
Altoida Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Predictive Biomarkers
5/16/2022
Altoida announced it has joined the Digital Medicine Society’s Alzheimer’s Disease and Related Dementias Digital Measures Development Project to support the advancement of its precision neuro-biomarkers platform.
-
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures
5/9/2022
Cognito Therapeutics today announced it has joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measures Development Project to support the advancement of its late-stage disease-modifying therapeutics pipeline for neurodegenerative diseases.
-
Advances in Biomarkers For Neurodegenerative Disease
4/11/2022
Neurodegenerative disease refers to a range of partly inherited conditions that destroy the neurons in the human brain due to the progressive damage of the nerve cells caused by diseases.
-
Akili to Speak at SXSW 2022 on Building a New Class of Disease-Modifying Digital Therapeutics
3/10/2022
Akili Interactive announced that co-founder and Chief Executive Officer, Eddie Martucci, will participate in a panel discussion at SXSW 2022, a conference that convenes a global community of digital creatives with a shared pursuit of forward-thinking, cutting-edge ideas.
-
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease
3/8/2022
Cognito Therapeutics and Aetion announced a strategic partnership to develop a validated predictive model to identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.
-
Robert Califf became the new commissioner of the U.S. Food & Drug Administration and emphasized the use of real-world evidence (RWE) in Agency decisions.
-
Cognito Therapeutics Announces Presentations for Novel Therapeutic in Alzheimer’s Disease at the 2022 American Academy of Neurology (AAN) Conference
3/3/2022
Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts, including one which was selected for a presentation at the “Neuroscience in Clinic” session, at the American Academy of Neurology Conference.
-
Cognito Therapeutics to Present Virtual Symposium “Predicting Alzheimer’s Disease Progression with Neurophysiological Markers” at 2022 AD/PD Conference
3/1/2022
Cognito Therapeutics announced today it will present a virtual symposium featuring a panel of leading neuroscientists to discuss neurophysiological markers in Alzheimer’s Disease progression.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
1/27/2022
Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).
-
14th Annual Biotech Showcase™ Brings Together One of The Largest, Most Informative Biotech Investment Conferences Virtually
1/20/2022
In its 14th year, Biotech Showcase™, co-produced by Demy-Colton and EBD Group, welcomed over 2,400 attendees, nearly a 10 percent increase from last year, together with over 860 investors, and 320 presenting companies.
-
ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment
1/7/2022
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on Jan. 11, 2022 from 8 AM to 9 AM PST.
-
Cognito Therapeutics Appoints Jennifer Newberger as Head of Regulatory and Compliance
12/14/2021
Cognito Therapeutics announced today the appointment of Jennifer Newberger as Vice President, Head of Regulatory Affairs and Compliance.
-
Digital Therapeutics Alliance Elects Cognito Therapeutics’ Everett Crosland to its Board of Directors
12/8/2021
Digital Therapeutics Alliance today announced the election of Everett Crosland, Chief Commercial Officer, Cognito Therapeutics to its Board of Directors.
-
Cognito Therapeutics CEO Brent Vaughan to Speak at CODE Conference 2021
9/15/2021
Cognito Therapeutics announced today its CEO Brent Vaughan will speak at CODE Conference , in Beverly Hills, CA, September 27-29, 2021 to discuss Cognito’s ground-breaking technology that has shown the promise of slowing or stopping the progression of Alzheimer’s and its potential to fundamentally expand human cognitive performance.
-
Cognito Therapeutics Announces Formation of Payor Advisory Board
9/8/2021
Cognito Therapeutics announced today the formation of a first-in-category Payor Advisory Board to enable day one payor coverage upon approval and insure timely and broad patient access to Cognito’s breakthrough treatment for Alzheimer’s.